[go: up one dir, main page]

MX2021000740A - Composiciones y metodos para el tratamiento del cancer. - Google Patents

Composiciones y metodos para el tratamiento del cancer.

Info

Publication number
MX2021000740A
MX2021000740A MX2021000740A MX2021000740A MX2021000740A MX 2021000740 A MX2021000740 A MX 2021000740A MX 2021000740 A MX2021000740 A MX 2021000740A MX 2021000740 A MX2021000740 A MX 2021000740A MX 2021000740 A MX2021000740 A MX 2021000740A
Authority
MX
Mexico
Prior art keywords
compositions
cancer
treatment
methods
formulated
Prior art date
Application number
MX2021000740A
Other languages
English (en)
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of MX2021000740A publication Critical patent/MX2021000740A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones y compuestos de la fórmula I y fórmula II, incluyendo conjugados inhibidores de la síntesis de ácidos nucleicos, o sus polimorfos, enantiómeros, estereoisómeros, solvatos e hidratos de los mismos. Estos conjugados pueden formularse como composiciones farmacéuticas. Las composiciones farmacéuticas pueden formularse para su administración oral, administración intravenosa, en solución, jarabe, sobre, transdérmica o inyección. Estas composiciones pueden utilizarse para el tratamiento del cáncer o de sus complicaciones asociadas.
MX2021000740A 2018-08-03 2019-07-09 Composiciones y metodos para el tratamiento del cancer. MX2021000740A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841029367 2018-08-03
PCT/IB2019/055827 WO2020026054A1 (en) 2018-08-03 2019-07-09 Compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2021000740A true MX2021000740A (es) 2021-03-26

Family

ID=69231514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000740A MX2021000740A (es) 2018-08-03 2019-07-09 Composiciones y metodos para el tratamiento del cancer.

Country Status (11)

Country Link
US (1) US20210171564A1 (es)
EP (1) EP3817732A4 (es)
JP (1) JP2021534085A (es)
KR (1) KR20210057025A (es)
AU (1) AU2019313484A1 (es)
BR (1) BR112021001652A2 (es)
CA (1) CA3108362A1 (es)
IL (1) IL280262A (es)
MX (1) MX2021000740A (es)
SG (1) SG11202100411TA (es)
WO (1) WO2020026054A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022049462A1 (en) * 2020-09-05 2022-03-10 Cellix Bio Private Limited Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
EP1311524A2 (en) * 2000-08-09 2003-05-21 Kolon Industries, Inc. 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
CN101080417B (zh) * 2004-12-17 2011-01-19 伊莱利利公司 吉西他滨的酰胺前体药物、其组合物以及应用
US20080262215A1 (en) * 2007-04-23 2008-10-23 Chemagis Ltd. Gemcitabine production process
ES2544803T3 (es) * 2009-01-23 2015-09-04 Euro-Celtique S.A. Derivados del ácido hidroxámico
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
RU2770081C2 (ru) * 2016-06-28 2022-04-14 Селликс Био Прайвет Лимитед Композиции и способы для лечения рака

Also Published As

Publication number Publication date
CA3108362A1 (en) 2020-02-06
SG11202100411TA (en) 2021-02-25
KR20210057025A (ko) 2021-05-20
US20210171564A1 (en) 2021-06-10
EP3817732A1 (en) 2021-05-12
WO2020026054A1 (en) 2020-02-06
IL280262A (en) 2021-03-01
JP2021534085A (ja) 2021-12-09
BR112021001652A2 (pt) 2021-05-04
AU2019313484A2 (en) 2021-02-25
EP3817732A4 (en) 2022-06-08
AU2019313484A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
MX2022008066A (es) Compuestos triciclicos sustituidos.
PH12022551014A1 (en) Substituted tricyclic compounds
PH12017502331A1 (en) 1,4-substituted piperidine derivatives
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
GEP20166484B (en) Protein kinase inhibitors
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
MX2020007152A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
MX2021000740A (es) Composiciones y metodos para el tratamiento del cancer.
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
PH12021550258A1 (en) Cdk8/19 inhibitors
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
MX387330B (es) Composiciones y metodos para el tratamiento de sindrome de intestino irritable
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
MX386208B (es) Composiciones y métodos para el tratamiento de pólipos gastrointestinales.
TW201612188A (en) The L-proline complex, monohydrate and crystal of a sodium-glucose contransporter 2 inhibitor